Disease Domain | Count |
---|---|
Nervous System Diseases | 5 |
Neoplasms | 2 |
Immune System Diseases | 2 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 8 |
Diagnostic radiopharmaceuticals | 8 |
Chemical drugs | 1 |
Recombinant vector vaccine | 1 |
Prophylactic vaccine | 1 |
Target- |
Mechanism Immunostimulants |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism κ opioid receptor antagonists |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TSPO inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2026 |
Sponsor / Collaborator ![]() [+1] |
Start Date01 May 2025 |
Sponsor / Collaborator |
Start Date01 Apr 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
TS-161 ( mGluR2 x mGluR3 ) | Depressive Disorder, Treatment-Resistant More | Phase 2 |
Aticaprant ( κ opioid receptor ) | Tobacco Use Disorder More | Phase 2 |
[11C]PS13 | Multiple Sclerosis More | Phase 2 |
[18F]-PBR-06 ( TSPO ) | Alzheimer Disease More | Phase 2 |
BCG vaccine(Max Planck Institute For Infection Biology) | HIV Infections More | Phase 1/2 |